Anthracyclines versus No Anthracyclines in the Neoadjuvant Strategy for HER2+ Breast Cancer: Real-World Evidence

CONCLUSION: This study reports real-world evidence showing similar pCR and EFS outcomes with treatment regimens with and without AC and raises awareness of possible overtreatment and long-term toxicity in some patients with HER2+ EBC with the use of AC.PMID:37479867 | DOI:10.1007/s40261-023-01291-6

Source: Clinical Breast Cancer - July 21, 2023 Category: Cancer & Oncology Authors: In ês Soares de Pinho Paulo Luz Lucy Alves Raquel Lopes-Br ás Vanessa Patel Miguel Esperan ça-Martins Lisa Gon çalves Ritas Freitas Diana Sim ão Maria Rold án Galnares Isabel Fernandes Silvia Artacho Criado Salvador Gamez Casado Jose Baena Ca ñada Source Type: research